WHO Watch Team
IP at World Health Assembly Private monopolies hinder progress on public health: intellectual property at the 75th World Health Assembly

Obstruction by pharmaceutical companies from the Global North and misuse of monopoly privileges continue to slow down research into new vaccines and medicines, with disastrous effects for people’s health in the Global South. Discussions at the 75th World Health Assembly did little to address this

World Health Assembly World Health Assembly falls short of insulating food and alcohol plans from commercial interests

Without stronger action to counter the influence of transnational alcohol and food companies, industry-propelled health harm will continue to persist

Access to insulin: A tale of 100 years of disparity

A century after the discovery of insulin, quality-assured access remains hindered by high prices. The WHO resolution for transparency in pricing of insulin aims at dealing with Big Pharma market monopoly

World Health Assembly 74: One year into the pandemic

One year into the pandemic, the World Health Assembly is holding its annual meeting. The continued financial challenges loomed over delegates as they discussed the possibility of a Pandemic Treaty, local production of medicines, and WHO’s COVID-19 response

As World Health Assembly starts, solidarity is missing from the agenda

The 74th World Health Assembly that began on Monday will have to deal with a host of challenges at a time when the COVID-19 pandemic has exposed the stark inequalities in every aspect of health across the globe